RU2337911C2 - Производные гуанидина и их применение в качестве антагонистов рецептора нейропептида ff - Google Patents

Производные гуанидина и их применение в качестве антагонистов рецептора нейропептида ff Download PDF

Info

Publication number
RU2337911C2
RU2337911C2 RU2005132308/04A RU2005132308A RU2337911C2 RU 2337911 C2 RU2337911 C2 RU 2337911C2 RU 2005132308/04 A RU2005132308/04 A RU 2005132308/04A RU 2005132308 A RU2005132308 A RU 2005132308A RU 2337911 C2 RU2337911 C2 RU 2337911C2
Authority
RU
Russia
Prior art keywords
guanidine
tetrahydrobenzothiazol
formate
methyl
group
Prior art date
Application number
RU2005132308/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2005132308A (ru
Inventor
Эва КАРОФФ (FR)
Эва КАРОФФ
Маттиас ШТЕГЕР (CH)
Маттиас ШТЕГЕР
Оливье ВАЛЬДЕНЕР (CH)
Оливье ВАЛЬДЕНЕР
Ан ФЕХЕР (CH)
Аня ФЕХЕР
Фолькер БРОЙ (DE)
Фолькер БРОЙ
Курт ХИЛЬПЕРТ (CH)
Курт ХИЛЬПЕРТ
Хайнц ФРЕТЦ (CH)
Хайнц ФРЕТЦ
Томас ГИЛЛЕР (CH)
Томас ГИЛЛЕР
Original Assignee
Актелион Фармасьютикалз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Актелион Фармасьютикалз Лтд. filed Critical Актелион Фармасьютикалз Лтд.
Publication of RU2005132308A publication Critical patent/RU2005132308A/ru
Application granted granted Critical
Publication of RU2337911C2 publication Critical patent/RU2337911C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2005132308/04A 2003-03-20 2004-03-22 Производные гуанидина и их применение в качестве антагонистов рецептора нейропептида ff RU2337911C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH466/03 2003-03-20
CH4662003 2003-03-20

Publications (2)

Publication Number Publication Date
RU2005132308A RU2005132308A (ru) 2006-03-20
RU2337911C2 true RU2337911C2 (ru) 2008-11-10

Family

ID=32996985

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005132308/04A RU2337911C2 (ru) 2003-03-20 2004-03-22 Производные гуанидина и их применение в качестве антагонистов рецептора нейропептида ff

Country Status (15)

Country Link
US (1) US7727979B2 (enExample)
EP (1) EP1608662A1 (enExample)
JP (1) JP2006520330A (enExample)
KR (1) KR20050107611A (enExample)
CN (1) CN100355758C (enExample)
AR (1) AR043662A1 (enExample)
AU (1) AU2004222224A1 (enExample)
BR (1) BRPI0408357A (enExample)
CA (1) CA2518679A1 (enExample)
CL (1) CL2004000553A1 (enExample)
MX (1) MXPA05009855A (enExample)
NO (1) NO20054743L (enExample)
RU (1) RU2337911C2 (enExample)
TW (1) TW200510434A (enExample)
WO (1) WO2004083218A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2004000553A1 (es) 2003-03-20 2005-02-04 Actelion Pharmaceuticals Ltd Uso de compuestos derivados de guanidina como antagonistas del receptor de neuropeptido ff; compuestos derivados de guanidina; procedimientos de preparacion; y composicion farmaceutica que los comprende.
CA2560128A1 (en) * 2004-03-19 2005-10-06 Dipharma S.P.A. Intermediates for the preparation of pramipexole
JP2009543785A (ja) 2006-07-14 2009-12-10 メルク エンド カムパニー インコーポレーテッド 架橋ジアゼパンオレキシン受容体アンタゴニスト
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
JP2010527924A (ja) 2007-05-18 2010-08-19 メルク・シャープ・エンド・ドーム・コーポレイション オキソ架橋ジアゼパンオレキシン受容体アンタゴニスト
US8030495B2 (en) 2007-05-23 2011-10-04 Coleman Paul J Cyclopropyl pyrrolidine orexin receptor antagonists
ES2379744T3 (es) 2007-05-23 2012-05-03 Merck Sharp & Dohme Corp. Antagonistas de piridil-piperidina de los receptores de orexinas
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
PH12013501686A1 (en) 2011-02-25 2017-10-25 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
CA2880901A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US10344002B2 (en) 2016-09-26 2019-07-09 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
WO2018152134A1 (en) 2017-02-14 2018-08-23 Research Triangle Institute Proline-based neuropeptide ff receptor modulators
EP3762008A1 (en) * 2018-03-09 2021-01-13 Centre National de la Recherche Scientifique Hybrid mu opioid receptor and neuropeptide ff receptor binding molecules, their methods of preparation and applications in therapeutic treatment
CN110093348B (zh) * 2018-12-05 2022-11-29 西北工业大学 增强小鼠NPFFR2基因表达的shRNA
CA3144527A1 (en) 2019-08-06 2021-02-11 Domain Therapeutics 5-heteroaryl-pyridin-2-amine confounds as neuropeptide ff receptor antagonists
CN112341404B (zh) * 2019-08-09 2023-05-23 成都苑东生物制药股份有限公司 噻唑类衍生物或盐、异构体、其制备方法及用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1140387A (en) * 1965-07-23 1969-01-15 Thomae Gmbh Dr K 4,5,6,7-tetrahydro-thiazolo-[5,4-c]pyridines
SU664965A1 (ru) * 1977-02-01 1979-05-30 Уральский ордена Трудового Красного Знамени политехнический институт им.С.М.Кирова 3-Замещенные пиридо /2,3-е/-1,2,4тиадиазин-1,1-диоксиды,обладающие анальгетическим действием
US4624956A (en) * 1983-12-16 1986-11-25 Farmitalia Carlo Erba Ulcer and gastric secretion inhibiting 4,5,6,7-tetrahydrothiazole[5,4-c]pyridine derivatives
US4716228A (en) * 1985-03-23 1987-12-29 Farmitalia Carlo Erba S.P.A. Condensed 2-substituted thiazole derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795257A (fr) 1972-02-10 1973-08-09 Thomae Gmbh Dr K Nouveaux oxazols
JPS60226810A (ja) 1984-04-25 1985-11-12 Ikeda Mohandou:Kk 抗潰瘍剤
JPS6233158A (ja) 1985-08-02 1987-02-13 Shionogi & Co Ltd ベンズイミダゾ−ル誘導体および抗潰瘍剤
WO1989005643A1 (en) 1987-12-18 1989-06-29 Pfizer Inc. Heterocyclic-substituted quinoline-carboxylic acids
KR0168978B1 (ko) * 1995-07-12 1999-01-15 김종인 헤테로고리 접합 티아졸 유도체
JPH0959258A (ja) * 1995-08-11 1997-03-04 Ono Pharmaceut Co Ltd グアニジル誘導体
FR2814367B1 (fr) 2000-09-25 2008-12-26 Inst Nat Sante Rech Med Ligands du recepteur npff pour le traitement de la douleur et des hyperalgies
CL2004000553A1 (es) 2003-03-20 2005-02-04 Actelion Pharmaceuticals Ltd Uso de compuestos derivados de guanidina como antagonistas del receptor de neuropeptido ff; compuestos derivados de guanidina; procedimientos de preparacion; y composicion farmaceutica que los comprende.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1140387A (en) * 1965-07-23 1969-01-15 Thomae Gmbh Dr K 4,5,6,7-tetrahydro-thiazolo-[5,4-c]pyridines
SU664965A1 (ru) * 1977-02-01 1979-05-30 Уральский ордена Трудового Красного Знамени политехнический институт им.С.М.Кирова 3-Замещенные пиридо /2,3-е/-1,2,4тиадиазин-1,1-диоксиды,обладающие анальгетическим действием
US4624956A (en) * 1983-12-16 1986-11-25 Farmitalia Carlo Erba Ulcer and gastric secretion inhibiting 4,5,6,7-tetrahydrothiazole[5,4-c]pyridine derivatives
US4716228A (en) * 1985-03-23 1987-12-29 Farmitalia Carlo Erba S.P.A. Condensed 2-substituted thiazole derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Marinko P et al "A convenient synthesis of 4-aminomethyl-4,5,6,7-tetrahydro-1,3-benzothiazole arginine side-chain mimitics", Tetrahedron letters, v.42, no 50, 10.12.2001, p.8911-8913. *

Also Published As

Publication number Publication date
KR20050107611A (ko) 2005-11-14
CL2004000553A1 (es) 2005-02-04
CA2518679A1 (en) 2004-09-30
WO2004083218A1 (de) 2004-09-30
TW200510434A (en) 2005-03-16
JP2006520330A (ja) 2006-09-07
NO20054743L (no) 2005-10-14
CN100355758C (zh) 2007-12-19
BRPI0408357A (pt) 2006-03-21
AU2004222224A1 (en) 2004-09-30
RU2005132308A (ru) 2006-03-20
MXPA05009855A (es) 2005-12-06
AR043662A1 (es) 2005-08-03
US20060194788A1 (en) 2006-08-31
EP1608662A1 (de) 2005-12-28
US7727979B2 (en) 2010-06-01
CN1761673A (zh) 2006-04-19

Similar Documents

Publication Publication Date Title
RU2337911C2 (ru) Производные гуанидина и их применение в качестве антагонистов рецептора нейропептида ff
TWI465452B (zh) 螺-吲哚酮化合物之鏡像異構物及其作為治療劑之用途
JP6626454B2 (ja) Trpa1モジュレーター
JP2010522690A (ja) 三環式スピロオキシインドール誘導体および治療薬としてのその使用
US20250115576A1 (en) Therapeutic compounds and methods of use thereof
US20250042917A1 (en) Therapeutic compounds and methods of use thereof
CN105492430B (zh) 取代的苯并噁唑及其使用方法
JP2007504176A (ja) グアニジン誘導体
AU2015224493B2 (en) Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
ZA200508486B (en) Guanidine derivatives and use thereof as neuropeptide FF receptor antagonists
TW202000651A (zh) 治療性組成物及其使用方法
HK1168854B (en) Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20090323